vs
Amneal Pharmaceuticals, Inc.（AMRX）とIES Holdings, Inc.（IESC）の財務データ比較。上の社名をクリックして会社を切り替えられます
IES Holdings, Inc.の直近四半期売上が大きい（$871.0M vs $722.5M、Amneal Pharmaceuticals, Inc.の約1.2倍）。Amneal Pharmaceuticals, Inc.の純利益率が高く（10.8% vs 10.5%、差は0.3%）。IES Holdings, Inc.の前年同期比売上増加率が高い（16.2% vs 3.9%）。過去8四半期でIES Holdings, Inc.の売上複合成長率が高い（11.1% vs 1.5%）
アムニールファーマシューティカルズは米国の上場製薬企業で、後発医薬品と専門医薬品の開発・製造・流通を事業の柱としています。本社はニュージャージー州ブリッジウォーターに位置し、米国最大級の後発医薬品メーカーの1つです。
IES Holdings, Inc.は旧社名Integrated Electrical Services, Inc.で、統合電気・技術システムの設計・設置を手がけるほか、データセンター、住宅、商業施設・工業施設など多様な末端市場向けにインフラ関連製品・サービスを提供している。
AMRX vs IESC — 直接比較
損益計算書 — Q1 FY2026 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $722.5M | $871.0M |
| 純利益 | $78.0M | $91.8M |
| 粗利率 | 44.3% | 25.3% |
| 営業利益率 | — | 11.2% |
| 純利益率 | 10.8% | 10.5% |
| 売上前年比 | 3.9% | 16.2% |
| 純利益前年比 | 217.0% | 59.1% |
| EPS（希薄化後） | $0.19 | $4.51 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $871.0M | ||
| Q3 25 | $784.5M | $897.8M | ||
| Q2 25 | $724.5M | $890.2M | ||
| Q1 25 | $695.4M | $834.0M | ||
| Q4 24 | $730.5M | $749.5M | ||
| Q3 24 | $702.5M | $775.8M | ||
| Q2 24 | $701.8M | $768.4M |
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $91.8M | ||
| Q3 25 | $2.4M | $102.3M | ||
| Q2 25 | $22.4M | $79.3M | ||
| Q1 25 | $12.2M | $72.6M | ||
| Q4 24 | $-31.1M | $57.7M | ||
| Q3 24 | $-156.0K | $65.5M | ||
| Q2 24 | $6.0M | $66.6M |
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 25.3% | ||
| Q3 25 | 34.9% | 26.0% | ||
| Q2 25 | 39.5% | 26.9% | ||
| Q1 25 | 36.8% | 25.0% | ||
| Q4 24 | 36.0% | 23.8% | ||
| Q3 24 | 38.4% | 24.0% | ||
| Q2 24 | 35.6% | 25.3% |
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 11.2% | ||
| Q3 25 | 9.0% | 11.6% | ||
| Q2 25 | 15.4% | 12.6% | ||
| Q1 25 | 14.4% | 11.1% | ||
| Q4 24 | 10.4% | 10.0% | ||
| Q3 24 | 12.6% | 9.7% | ||
| Q2 24 | 13.6% | 11.7% |
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 10.5% | ||
| Q3 25 | 0.3% | 11.4% | ||
| Q2 25 | 3.1% | 8.9% | ||
| Q1 25 | 1.8% | 8.7% | ||
| Q4 24 | -4.3% | 7.7% | ||
| Q3 24 | -0.0% | 8.4% | ||
| Q2 24 | 0.9% | 8.7% |
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $4.51 | ||
| Q3 25 | $0.01 | $4.99 | ||
| Q2 25 | $0.07 | $3.81 | ||
| Q1 25 | $0.04 | $3.50 | ||
| Q4 24 | $-0.10 | $2.72 | ||
| Q3 24 | $0.00 | $3.06 | ||
| Q2 24 | $0.02 | $2.67 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | — | $258.7M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | — | $961.1M |
| 総資産 | — | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $258.7M | ||
| Q3 25 | $201.2M | $231.8M | ||
| Q2 25 | $71.5M | $168.3M | ||
| Q1 25 | $59.2M | $88.3M | ||
| Q4 24 | $110.6M | $112.0M | ||
| Q3 24 | $74.0M | $135.8M | ||
| Q2 24 | $43.8M | $44.9M |
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $961.1M | ||
| Q3 25 | $-109.5M | $884.0M | ||
| Q2 25 | $-112.1M | $781.4M | ||
| Q1 25 | $-131.7M | $705.8M | ||
| Q4 24 | $-109.3M | $652.4M | ||
| Q3 24 | $-93.4M | $611.1M | ||
| Q2 24 | $-57.5M | $567.5M |
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $1.7B | ||
| Q3 25 | $3.6B | $1.6B | ||
| Q2 25 | $3.4B | $1.5B | ||
| Q1 25 | $3.4B | $1.4B | ||
| Q4 24 | $3.5B | $1.3B | ||
| Q3 24 | $3.5B | $1.2B | ||
| Q2 24 | $3.5B | $1.2B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $27.7M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $-18.9M |
| FCFマージンFCF / 売上 | — | -2.2% |
| 設備投資強度設備投資 / 売上 | — | 5.3% |
| キャッシュ転換率営業CF / 純利益 | — | 0.30× |
| 直近12ヶ月FCF直近4四半期 | — | $175.9M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $27.7M | ||
| Q3 25 | $118.5M | $132.0M | ||
| Q2 25 | $83.8M | $92.0M | ||
| Q1 25 | $7.4M | $24.8M | ||
| Q4 24 | $118.1M | $37.3M | ||
| Q3 24 | $141.8M | $92.8M | ||
| Q2 24 | $39.7M | $82.9M |
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $-18.9M | ||
| Q3 25 | $106.2M | $112.0M | ||
| Q2 25 | $61.0M | $74.8M | ||
| Q1 25 | $-5.8M | $7.9M | ||
| Q4 24 | $102.9M | $24.1M | ||
| Q3 24 | $124.8M | $78.5M | ||
| Q2 24 | $29.0M | $65.4M |
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | -2.2% | ||
| Q3 25 | 13.5% | 12.5% | ||
| Q2 25 | 8.4% | 8.4% | ||
| Q1 25 | -0.8% | 0.9% | ||
| Q4 24 | 14.1% | 3.2% | ||
| Q3 24 | 17.8% | 10.1% | ||
| Q2 24 | 4.1% | 8.5% |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 5.3% | ||
| Q3 25 | 1.6% | 2.2% | ||
| Q2 25 | 3.2% | 1.9% | ||
| Q1 25 | 1.9% | 2.0% | ||
| Q4 24 | 2.1% | 1.8% | ||
| Q3 24 | 2.4% | 1.8% | ||
| Q2 24 | 1.5% | 2.3% |
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 0.30× | ||
| Q3 25 | 50.00× | 1.29× | ||
| Q2 25 | 3.74× | 1.16× | ||
| Q1 25 | 0.61× | 0.34× | ||
| Q4 24 | — | 0.65× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | 6.62× | 1.24× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
IESC
| Communications | $351.9M | 40% |
| Single Family Electrical Contracts | $137.0M | 16% |
| Custom Engineered Solutions | $116.0M | 13% |
| Commercialand Industrial | $94.8M | 11% |
| Single Family Contracts Plumbing HVAC | $82.9M | 10% |
| Multi Familyand Other | $64.2M | 7% |
| Industrial Services | $24.2M | 3% |
